Badanie doustnego stosowania tazemetostatu u pacjentów z umiarkowanymi i ciężkimi zaburzeniami czynności wątroby z zaawansowanymi nowotworami
Otwarte badanie fazy I dotyczące farmakokinetyki i bezpieczeństwa wielodawkowego tazemetostatu doustnego u pacjentów z umiarkowanymi i ciężkimi zaburzeniami czynności wątroby i zaawansowanymi nowotworami
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat.
The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function.
An advanced malignancy is a cancer that has recurred (come back) after prior treatment or hasn't controlled with treatment.
The trial will also study the safety of the study drug in participants (how well it is tolerated).
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
The study will be conducted in 2 parts for subjects with advanced malignancies and either normal liver function, or advanced malignancies and moderate, or severe hepatic impairment. Subjects in Part 1 of the study will receive a single oral, 800 mg dose of tazemetostat on Day 1 and Day 15. In addition, the subjects will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily from Day 5 to Day 14. Blood samples for PK analysis will be obtained on Day 1 through Day 4 and again on Day 15 through Day 18. Part 1 ends on Day 18.
Subjects continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles beginning on Day 19 until Investigator-assessed clinical progression per standard practice, or unacceptable toxicity, or until another discontinuation criterion is met. Subjects must have an end of study visit for safety assessment 30 days after the last dose of tazemetostat or prior to initiation of a subsequent anticancer therapy, whichever occurs first. Supplementary study conduct information not mandated to be present in this protocol is provided in the accompanying procedure manuals (i.e., laboratory, pharmacy, ECG manuals). Such manuals will provide the site personnel with administrative and detailed technical information that does not impact subject safety.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Antwerp
-
Edegem, Antwerp, Belgia, 2650
- Antwerp University Hospital
-
-
-
-
-
Bordeaux, Francja, 33076
- Institut Bergonie
-
Lille, Francja, 59020
- Centre Oscar Lambret
-
Strasbourg, Francja
- Institut de Cancérologie Strasbourg Europe
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polska, 60693
- MedPolonia
-
-
-
-
Florida
-
Lake Mary, Florida, Stany Zjednoczone, 32746
- Florida Cancer Specialists & Research Institute
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
-
-
Michigan
-
Royal Oak, Michigan, Stany Zjednoczone, 48073
- Hematology Oncology Consultants
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89014
- Comprehensive Cancer Center of Nevada
-
-
New Jersey
-
New Brunswick, New Jersey, Stany Zjednoczone, 08901
- Rutgers Cancer Institute
-
-
Ohio
-
Canton, Ohio, Stany Zjednoczone, 44718
- Gabrail Cancer Center
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75230
- Mary Crowley Cancer Research
-
-
Virginia
-
Fairfax, Virginia, Stany Zjednoczone, 22031
- Virginia Cancer Specialists
-
-
-
-
-
Bratislava, Słowacja, 831 01
- Summit Clinical Research, s.r.o
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male or female ≥ 18 years age at the time of consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
- Has the ability to understand informed consent and provided signed written informed consent.
- Life expectancy of > 3 months.
- Histologically and/or cytologically confirmed advanced metastatic or unresectable solid tumors has progressed after treatment for which there are no standard therapies available OR histologically and/or cytologically confirmed hematological malignancies that have relapsed, or refractory disease following at least 2 standard lines of systemic therapy for which there are no standard therapies available.
- Must have evaluable or measurable disease.
- Has all prior treatment (i.e., chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to ≤ Grade 1 per NCI CTCAE, Version 5.0 or are clinically stable and not clinically significant, at time of consent.
- All subjects must have completed any prior chemotherapy, targeted therapy and major surgery, ≥ 28 days before study entry. For daily or weekly chemotherapy without the potential for delayed toxicity, a washout period of 14 days may be acceptable, and questions related to this can be discussed with the Medical Monitor.
- Has adequate hematologic (bone marrow [BM] and coagulation factors), and renal function.
- Able to swallow and retain orally-administered medication and without clinically significant gastrointestinal abnormalities that could alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
- Subjects with abnormal hepatic function will be eligible and will be grouped according to established criteria. Subjects with active hemolysis will be excluded.
- Manual differential with no significant morphologic abnormalities on complete blood count (CBC) testing.
- Male subjects must have had a successful vasectomy OR must either practice complete abstinence or agree to use a latex or synthetic condom during sexual contact with a female of childbearing potential from the first dose of study drug, during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation.
- Females of childbearing potential must have a negative serum pregnancy test at screening and within 24 hours prior to the first dose of study drug. All females will be considered of childbearing potential unless they are naturally postmenopausal or have been sterilized.
- Females of childbearing potential (FCBP) must either practice complete abstinence or agree to use a highly effective method of contraception beginning at least 28 days prior to the first dose of study drug, during study treatment (including during dose interruptions), and for 6 months after study drug discontinuation.
- Has a QT interval corrected by Fridericia's formula (QTcF) ≤480 msec.
- Subjects with diagnosed human immunodeficiency virus (HIV) are eligible to participate in the study if they meet established criteria.
Exclusion Criteria:
- Prior exposure to tazemetostat or other inhibitor(s) of EZH2.
- Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam. Subjects with primary glioblastoma multiforme are excluded.
- Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders. Subjects on anticoagulation with low molecular weight heparin are allowed.
- Known hypersensitivity to any of the components of tazemetostat.
- Concurrent investigational agent or anticancer therapy. NOTE: Megestrol (Megace) if used as an appetite stimulant is allowed.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements.
- Have a known active infection with hepatitis B virus (HBV, as measured by positive hepatitis B surface antigen, hepatitis C virus (HCV, as measured by positive hepatitis C antibody), OR human T-cell lymphotropic virus 1.
- Subjects taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's Wort).
- Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from 24 hours prior to the first dose of study drug until the last dose of study drug.
- Any condition or medical problem in addition to the underlying malignancy and organ dysfunction that the Investigator feels would pose unacceptable risk.
- Has thrombocytopenia, neutropenia, or anemia of grade ≥3 (per CTCAE 5.0 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS).
- Has abnormalities known to be associated with MDS and myeloproliferative neoplasms (MPN) observed in cytogenetic testing and DNA sequencing.
- Has a prior history of T-LBL/T-ALL.
- Ingestion of alcohol and smoking is not permitted any time during the study.
- History of drug abuse (including alcohol) within the last 6 months prior to screening.
- Severe hepatic encephalopathy (Grade >2) or degree of CNS impairment which the Investigator considers sufficiently serious to interfere with the informed consent, the conduct, the completion, or the results of this trial, or constitutes an unacceptable risk to the subject.
- History of liver transplantation.
- Advanced ascites or ascites that require drainage and albumin supplementation, as judged by the Investigator.
- Acute damage of the liver with Grade 4 AST/ALT values at screening or admission.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Open label Tazemetostat
Part 1: Participants will receive a single oral 800 mg dose on day 1, and twice daily from day 5 to day 14. Participants will return to the clinical study unit on an out-patient basis from day 15 to day 18. A single oral 800 mg dose of tazemetostat will be administered on day 15. Part 2: Will begin on day 19 and participants continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles. |
Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle. Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of Tazemetostat and EPZ-6930 Following Single Dose Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following single dose administration. Pharmacokinetic (PK) parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Tazemetostat and EPZ-6930 Following Single Dose Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of AUC0-inf of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Single Dose Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Single Dose Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Observed Time at Maximum Plasma Concentration (Tmax) of Tazemetostat and EPZ-6930 Following Single Dose Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Observed Time at Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 Following Single Dose Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Terminal Elimination Half-Life of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Ramy czasowe: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
|
|
Part 1: Unbound Fraction of Tazemetostat and EPZ-6930 in Plasma (fu)
Ramy czasowe: Pre-dose (0 hour) on Day 15; 3 hours post-dose on Days 1 and 15 of Cycle 1 (each cycle was 28 days)
|
Blood samples were collected at specified timepoints for the assessment of fu of tazemetostat and its metabolite EPZ-6930 following single dose and multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method. |
Pre-dose (0 hour) on Day 15; 3 hours post-dose on Days 1 and 15 of Cycle 1 (each cycle was 28 days)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Parts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Ramy czasowe: From first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks
|
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this study drug. A serious AE was an AE that occurred during any study phase (i.e., baseline, treatment, washout, or follow-up), and at any dose of the study drug, comparator, or placebo, that fulfilled one or more of the following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect or was an important medical event that jeopardized the participant or required medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the day of the first dose of study drug through 30 days after the end of study drug. |
From first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Dyrektor Studium: Ipsen Medical Director, Ipsen
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- EZH-1201
- 2019-003368-36 (Numer EudraCT)
- 2024-517141-13-00 (Ctis)
- 2019 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .